GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Panbela Therapeutics Inc (OTCPK:PBLA) » Definitions » Profitability Rank

Panbela Therapeutics (Panbela Therapeutics) Profitability Rank : 2 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Panbela Therapeutics Profitability Rank?

Panbela Therapeutics has the Profitability Rank of 2. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Panbela Therapeutics's Operating Margin % for the quarter that ended in Mar. 2024 was %. As of today, Panbela Therapeutics's Piotroski F-Score is 3.


Competitive Comparison of Panbela Therapeutics's Profitability Rank

For the Biotechnology subindustry, Panbela Therapeutics's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Panbela Therapeutics's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Panbela Therapeutics's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Panbela Therapeutics's Profitability Rank falls into.



Panbela Therapeutics Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Panbela Therapeutics has the Profitability Rank of 2. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Panbela Therapeutics's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=-6.726 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Panbela Therapeutics has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Panbela Therapeutics Profitability Rank Related Terms

Thank you for viewing the detailed overview of Panbela Therapeutics's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Panbela Therapeutics (Panbela Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
712 Vista Boulevard, Suite 305, Waconia, MN, USA, 55387
Panbela Therapeutics Inc is a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The Company's pipeline assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X), which provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity.
Executives
Jennifer K. Simpson director, officer: President and CEO C/O DELCATH SYSTEMS, INC., 810 SEVENTH AVENUE, SUITE 3505, NEW YORK NY 10019
Susan Horvath officer: V.P. of Finance & CFO 4645 ITHACA LANE, PLYMOUTH MN 55446
Jeffrey E. Jacob director 712 VISTA BLVD #305, WACONIA MN 55387
Daniel Donovan director 712 VISTA BLVD #305, WACONIA MN 55387
Paul W. Schaffer director 712 VISTA BLVD #305, WACONIA MN 55387
Arthur Fratamico director C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Ryan R. Gilbertson 2012 Irrevocable Trust 10 percent owner 1000 PARKER'S LAKE RD, WAYZATA MN 55391
Ryan Randall Gilbertson 10 percent owner 130 LAKE ST. WEST, WAYZATA MN 55391
Donald Robert Schemel director 712 VISTA BLVD #305, WACONIA MN 55387
Dalvir S Gill director 712 VISTA BLVD SUITE 305, WACONIA MN 55387
Scott Kellen officer: Chief Financial Officer 3405 ANNAPOLIS LANE, SUITE 200, MINNEAPOLIS MN 55447
Jeffrey S Mathiesen director 43334 SEVEN MILE RD., SUITE 1000, NORTHVILLE MI 48167
Paulson J Robert Jr director
Daniel E. Ryweck officer: Chief Financial Officer 712 VISTA BLVD #305, WACONIA MN 55387
Michael T. Cullen director 712 VISTA BLVD, #305, WACONIA MN 55387

Panbela Therapeutics (Panbela Therapeutics) Headlines

From GuruFocus

Panbela Announces 1-for-40 Reverse Stock Split effective January 13, 2023

By Stock market mentor Stock market mentor 01-12-2023

Panbela Announces 1-for-30 Reverse Stock Split Effective June 1, 2023

By sperokesalga sperokesalga 05-31-2023